Rebus Holdings Inc (RBSH)

[Kramrer]

Inspyr, like Gilead’s Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment. Inspyr merged with Lewis and Clark Pharmaceuticals several years ago and since then has developed a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. Their pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist.

While developing new A2A and A2B adenosine antagonists as well as dual A2A/A2B adenosine antagonist with improved drug like properties resulting in better bioavailability for the treatment of: